JP2023507981A5 - - Google Patents
Info
- Publication number
- JP2023507981A5 JP2023507981A5 JP2022537240A JP2022537240A JP2023507981A5 JP 2023507981 A5 JP2023507981 A5 JP 2023507981A5 JP 2022537240 A JP2022537240 A JP 2022537240A JP 2022537240 A JP2022537240 A JP 2022537240A JP 2023507981 A5 JP2023507981 A5 JP 2023507981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- approximately
- composition
- less
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025185522A JP2026027328A (ja) | 2019-12-18 | 2025-11-04 | 生物医薬組成物および関連の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949696P | 2019-12-18 | 2019-12-18 | |
| US62/949,696 | 2019-12-18 | ||
| US201962950595P | 2019-12-19 | 2019-12-19 | |
| US62/950,595 | 2019-12-19 | ||
| PCT/US2020/064241 WO2021126657A1 (en) | 2019-12-18 | 2020-12-10 | Biopharmaceutical compositions and related methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185522A Division JP2026027328A (ja) | 2019-12-18 | 2025-11-04 | 生物医薬組成物および関連の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507981A JP2023507981A (ja) | 2023-02-28 |
| JP2023507981A5 true JP2023507981A5 (https=) | 2023-12-19 |
Family
ID=74125707
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537240A Pending JP2023507981A (ja) | 2019-12-18 | 2020-12-10 | 生物医薬組成物および関連の方法 |
| JP2025185522A Pending JP2026027328A (ja) | 2019-12-18 | 2025-11-04 | 生物医薬組成物および関連の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185522A Pending JP2026027328A (ja) | 2019-12-18 | 2025-11-04 | 生物医薬組成物および関連の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230059341A1 (https=) |
| EP (1) | EP4077388A1 (https=) |
| JP (2) | JP2023507981A (https=) |
| KR (1) | KR20220129548A (https=) |
| CN (1) | CN115298218A (https=) |
| AU (2) | AU2020407007A1 (https=) |
| BR (1) | BR112022014694A2 (https=) |
| CA (1) | CA3164600A1 (https=) |
| IL (1) | IL293753A (https=) |
| MX (1) | MX2022007464A (https=) |
| WO (1) | WO2021126657A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4076385T1 (sl) * | 2019-12-20 | 2026-04-30 | Formycon Ag | Formulacije protiteles anti-pd1 |
| WO2024118587A1 (en) * | 2022-11-30 | 2024-06-06 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1-antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015017307A2 (pt) * | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| KR20180037275A (ko) * | 2015-08-24 | 2018-04-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 생물제약 조성물 |
| CN106999591B (zh) * | 2015-09-28 | 2021-02-23 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体制剂及其在医药上的应用 |
| LT3386541T (lt) * | 2015-12-07 | 2020-10-26 | Merck Patent Gmbh | Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą |
| JP2019533458A (ja) * | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
-
2020
- 2020-12-10 WO PCT/US2020/064241 patent/WO2021126657A1/en not_active Ceased
- 2020-12-10 CN CN202080094093.2A patent/CN115298218A/zh active Pending
- 2020-12-10 BR BR112022014694A patent/BR112022014694A2/pt not_active Application Discontinuation
- 2020-12-10 KR KR1020227024058A patent/KR20220129548A/ko active Pending
- 2020-12-10 EP EP20835967.9A patent/EP4077388A1/en active Pending
- 2020-12-10 MX MX2022007464A patent/MX2022007464A/es unknown
- 2020-12-10 AU AU2020407007A patent/AU2020407007A1/en not_active Abandoned
- 2020-12-10 CA CA3164600A patent/CA3164600A1/en active Pending
- 2020-12-10 IL IL293753A patent/IL293753A/en unknown
- 2020-12-10 US US17/785,506 patent/US20230059341A1/en active Pending
- 2020-12-10 JP JP2022537240A patent/JP2023507981A/ja active Pending
-
2025
- 2025-05-23 AU AU2025203823A patent/AU2025203823A1/en active Pending
- 2025-11-04 JP JP2025185522A patent/JP2026027328A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016177A5 (https=) | ||
| JP2025138634A (ja) | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 | |
| JP2022000436A (ja) | 高濃度抗体製剤 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| JP2023545926A5 (https=) | ||
| JP2020518599A5 (https=) | ||
| AU2018263837A1 (en) | Stable formulations of anti-CTLA4 antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof | |
| US20230116380A1 (en) | Long-acting gm-csf and methods of use | |
| JP2022532927A5 (https=) | ||
| US20220008533A1 (en) | Composition and methods of treating inflammatory and autoimmune diseases | |
| JP2022126791A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP7375252B2 (ja) | 結節性痒疹患者における皮膚病変およびそう痒の治療 | |
| US20250011416A1 (en) | Methods for the treatment of cardiovascular disease | |
| JP2019513748A5 (https=) | ||
| JP2023507981A5 (https=) | ||
| JP2026506286A (ja) | ミオスタチン活性化の選択的且つ強力な阻害抗体 | |
| JP2024540395A5 (https=) | ||
| CN111886252A (zh) | 促进胰岛细胞生长的方法 | |
| US20230227555A1 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| Graul et al. | The year's new drugs and biologics 2019 | |
| RU2745814C1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение | |
| US20160244520A1 (en) | Compositions and methods for treating psoriatic arthritis | |
| WO2025094976A1 (ja) | ヘモジデリンの沈着及び／又は滑膜肥厚の改善又は抑制剤 | |
| JP2023539736A5 (https=) | ||
| WO2025072725A9 (en) | Methods for the treatment of cardiovascular disease |